Abstract
In order to bring MDR analysis into a clinical setting, reproducible assays with clear cut off points to define MDR positivity must be used. Sensitivity can also be increased by combining the results of more than one assay. We have used a combination of flow cytometric assays to define MDR positive and negative blasts in 47 AML patients entered into MRC trials. Our primary test is a standardised and reproducible assay for anthracycline accumulation in which we use carboxylate microspheres to bind the fluorescent drug daunorubicin (dnr). Cells and beads are incubated concurrently with dnr. Cellular dnr accumulation is quantified as a cell: bead fluorescence ratio. Confirmatory assays for MDR comprise the cyclosporin modulation assay for rhodamine 123 uptake and also measurement of lung resistance protein and multidrug resistance associated protein (with LRP-56 and MRPr1 respectively).
27/47 (57%) samples had both low dnr accumulation and at least one positive confirmatory test (a modulated functional assay and/or protein overexpression) and were categorised as “confirmed MDR”. 15/47 patients (32%) were MDR negative in all 4 assays. 5/47 (11%) patients had unconfirmed low dnr accumulation. None of the patients in this cohort had high dnr accumulation alongside overexpressed LRP or MRP or functional P-glycoprotein. We believe that this approach to MDR analysis enhances the value of the highly reproducible functional assays. The use of a primary and confirmatory tests is also likely to improve specificity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Izquierdo MA, Scheffer GL, Flens MJ, Schroieijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-mediated multidrug resistance. Eur J Cancer 1996; 32A: 979–984.
Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996; 32A: 945–957.
Marie J-P. P-glycoprotein in adult hematological malignancies. Hematology/Oncology Clinics of N America 1995; 9:239–249.
Sonneveld P. Multidrug resistance in acute myeloid leukaemia. Balliere’s Clinical Haematology 1996; 9:185–203.
List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid-leukemia. Blood 1996; 87(6): 2464–2469.
Xu D, Knaust E, Pisa P, Palucka K, Lundenberg J, Arestrom I, Peterson C, Gruber A. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Br J Haematol 1996; 92:847–854.
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood 1997; 89(9): 3323–3329.
Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M. P-glycoprotein (pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997; 96:356–365.
Sonneveld P. Reversal of multidrug-resistance in acute myeloid-leukemia and other hematological malignancies. European Journal Of Cancer 1996; 32A(6): 1062–1069.
Estey E, Thall PF, Andreeff M, Beran M, Kantarjian H, O’Brien S, Escudier S, Robertson LE, Koller CA, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M. Use of Granulocyte Colony-Stimulating Factor Before, During and After Fludarabine Plus Cytarabine Induction Therapy of Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndromes: Comparison with Fludarabine plus Cytarabine Without Granulocyte Colony-Stimulating Factor. J Clin Oncol 1994; 12:671–678.
Beck WT, Grogan TM, Willman CL, Cordoncardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect p-glycoprotein-associated multidrug-resistance in patients’ tumors — consensus recommendations. Cancer Research 1996; 56(13): 3010–3020.
Sonneveld P, van den Engh GJ. Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cells determined by flow cytometry. Leukemia Research 1981; 5:251–257.
Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumor samples for p-glycoprotein and multidrug resistance-associated protein. European Journal Of Cancer 1996; 32A(6): 1024–1033.
Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele G, Wahrer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B, Schuurhuis GJ. Quality Control of multidrug resistance assays in adult acute leukaemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87:4809–4816.
Pallis M, Russell NH. Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. British Journal Of Haematology 1998; 100(1): 194–197.
te Boekhorst PAW, Lowenberg B, Vankapel J, Nooter K, Sonneveld P. Multidrug-resistant cells with high proliferative capacity determine response to therapy in acute myeloid-leukemia. Leukemia 1995; 9(6): 1025–1031.
Perrot JY, Faussat AM, Zhou DC, Zittoun R, Robert J, Marie JP. Evaluation multicentrique du phenotype MDR dans les leucemies: analyse intermediare de l’experience francaise. Bulletin Du Cancer 1996; 83(8): 634–640.
Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR-1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDRl+/efflux-cases. Blood 1995; 86:2329–2342.
Sincock PM, Ashman LK. Expression of c-kit and functional drug efflux are correlated in de novo acute myeloid leukaemia. Leukemia 1997; 11:1850–1857.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pallis, M., Turzanski, J., Langabeer, S., Russell, N.H. (1999). Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blasts. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive